Pia Herbolsheimer — AstraZeneca (Netherlands)

Area of research

Oncology · Pulmonary and Respiratory Medicine

Research interest

Research interests include HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, PARP inhibition in cancer therapy, and Advanced Breast Cancer Therapies.

Recent publications

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

New England Journal of Medicine 2025cited by 30position: middledoi

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.

Journal of Clinical Oncology 2025cited by 27position: middledoi

Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function

Breast Cancer Research and Treatment 2021cited by 31position: middledoi

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

The Lancet Oncology 2020cited by 453position: middledoi

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

Breast Cancer Research and Treatment 2019cited by 142position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Looking for a research collaborator?

Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.

Find collaborators in Oncology · Pulmonary and Respiratory Medicine →